Lenalidomide Based Immunotherapy in the Treatment of DLBCL
NCT03715296
·
clinicaltrials.gov ↗
UNKNOWN
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG:
Lenalidomide 25mg
Sponsor
Ruijin Hospital